Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a heart drug save brain function after a devastating stroke?

NCT ID NCT04362527

Disease control Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a medicine called milrinone, given through a vein, can help people recover better from a serious type of stroke called subarachnoid hemorrhage. After this stroke, many patients develop dangerous spasms in brain arteries that can cause further brain damage. The trial involved 370 adults with this condition and compared milrinone to a placebo to see if it improves recovery at 3 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

370 people

The number who actually took part.

Started

Aug 2020

Finished

Jan 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients hospitalized for aneurysmal SAH * First episode of vasospasm, with a diagnosis confirmed on cerebral arterial CT-scanner * Delay between diagnosis of vasospasm (done by CT-scanner) and inclusion ≤6 hours * Informed consent from a legal representative, or emergency procedure Exclusion Criteria: * Initial Glasgow score at 3 with a bilateral mydriasis * Moribund patient * Contraindication to Milrinone (notably obstructive cardiomyopathy…) * Cerebral infarction in the vasospasm area already present on the CT-scanner at the time of diagnosis (lack of expected benefit of treatment in this case according to medical judgement) * Cardiac failure requiring inotrope administration at the time of randomisation * Uncontrolled elevated intra-cranial pressure (i.e. ICP\>25 mmHg for more than 20 minutes) * Patient with flutter or cardiac arrhythmia (atrial fibrillation) poorly tolerated * Major metabolic disturbance (uncorrected hypokalaemia \<3 mmol/L) * Non-affiliation to French health care coverage, * Pregnant, breastfeeding or parturient woman * Adult deprived of their liberty by judicial or administrative decision * Adult under compulsory psychiatric care * Adult patient protected under the law (guardianship or trusteeship) * Inclusion in an interventional study using Milrinone, or evaluating a treatment of cerebral vasospasm or with the same primary endpoint (mRS at 3 months).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aneurysmal subarachnoid hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage intracranial vasospasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vasospasm

Contacts and locations

Locations

  • APHP Lariboisière

    Paris, France

  • CHU Angers

    Angers, France

  • CHU Besançon

    Besançon, France

  • CHU Bordeaux

    Bordeaux, France

  • CHU Brest

    Brest, France

  • CHU Caen

    Caen, France

  • CHU Dijon

    Dijon, France

  • CHU Lille

    Lille, France

  • CHU Nantes

    Nantes, France

  • CHU Rennes

    Rennes, France

  • CHU Tours

    Tours, France

  • Hôpital Civils de Lyon

    Lyon, France

  • Hôpital Fondation ROTHSCHILD

    Paris, France

  • Hôpital Gabriel Montpied

    Clermont-Ferrand, France

  • Hôpital Gui de Chauliac

    Montpellier, France

  • Hôpital de Hautepierre

    Strasbourg, 67098, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.